Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 616.50
Change Today +1.20 / 0.20%
Volume 43.6K
As of 10:39 AM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

redhill biopharma ltd (RDHL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/12/14 - $680.00
52 Week Low
11/18/14 - $295.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for REDHILL BIOPHARMA LTD (RDHL)

Related News

No related news articles were found.

redhill biopharma ltd (RDHL) Related Businessweek News

No Related Businessweek News Found

redhill biopharma ltd (RDHL) Details

RedHill Biopharma Ltd., a biopharmaceutical company, focuses on the development and acquisition of late clinical-stage, proprietary, and orally-administered drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers in Israel. The company’s pipeline of therapeutic candidates include RHB-105, which is in Phase III clinical trial, intended for the eradication of Helicobacter pylori infection; and RHB-104 that is in Phase III clinical trial for the treatment of Crohn's disease, in Phase IIa proof of concept clinical trial for the treatment of multiple sclerosis, and under pre-clinical studies for the treatment of rheumatoid arthritis. Its pipeline of therapeutic candidates also comprise BEKINDA, which is under review with FDA, for the prevention of chemotherapy and radiotherapy induced nausea and vomiting, and in Phase III clinical trial for the treatment of gastroenteritis and gastritis; and RHB-106 intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. In addition, the company’s pipeline of therapeutic candidates consist of MESUPRON, a urokinase-type plasminogen activator inhibitor targeting gastrointestinal and other solid tumor cancers, which has completed various Phase I clinical trials and two Phase II proof of concept clinical trials; RP101, a heat shock protein 27 inhibitor for the treatment of pancreatic and other gastrointestinal cancers, which has completed various Phase I and Phase II clinical trials; RIZAPORT, an oral thin film formulation of rizatriptan for acute migraines; and RHB-101 for the treatment of hypertension, heart failure, and left ventricular dysfunction. Further, its pipeline of proprietary products comprises ABC294640, a Phase II-stage orally-administered sphingosine kinase-2 inhibitor targeting various inflammatory, gastrointestinal, and oncology indications. The company was founded in 2009 and is based in Tel Aviv, Israel.

10 Employees
Last Reported Date: 02/26/15
Founded in 2009

redhill biopharma ltd (RDHL) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $280.2K
Deputy Chief Executive Officer of Finance & O...
Total Annual Compensation: $237.6K
Senior Vice President of Research & Developme...
Total Annual Compensation: $233.2K
Senior Vice President of Corporate & Product ...
Total Annual Compensation: $216.0K
Chief Business Officer
Total Annual Compensation: $199.3K
Compensation as of Fiscal Year 2014.

redhill biopharma ltd (RDHL) Key Developments

RedHill Biopharma Ltd. - Special Call

To provide an overview of H. pylori bacterial infection, the resulting unmet medical need and potential market opportunity for RHB-105 and to provide an update on the design and objectives of the ongoing ERADICATE Hp Phase III clinical study with RHB-105

RedHill Biopharma Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

RedHill Biopharma Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $4,755,000 against profit of $3,292,000 a year ago. Loss and comprehensive loss was $4,642,000 or $0.05 per diluted share against profit of $3,377,000 or $0.04 per diluted share a year ago. Net cash used in operating activities was $3,372,000 against net cash provided by operating activities $1,676,000 a year ago. Purchase of fixed assets was $2,000 against $25,000 a year ago. Purchase of intangible assets was $75,000. The change in operating loss mainly from revenues of $7.0 million from the Salix licensing transaction received in the first quarter of 2014.

RedHill Biopharma Ltd. Presents at Bio-Trinity, May-12-2015 02:00 PM

RedHill Biopharma Ltd. Presents at Bio-Trinity, May-12-2015 02:00 PM. Venue: Novotel London West, 1 Shortlands, London W6 8DR, United Kingdom. Speakers: Adi Frish, Senior Vice President of Business Development and Licensing.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDHL:IT 616.50 +1.20

RDHL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RDHL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RDHL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REDHILL BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at